Study of PETCT Scans Using Zirconium Zr 89 Crefmirlimab Berdoxam to Image CD8 T Cells in Metastatic Non-Small Cell Lung Cancer During Engineered TIL Therapy

What this Trial Is About

Researchers are evaluating the use of PETCT scans with an imaging agent called zirconium Zr 89 crefmirlimab berdoxam to safely and effectively identify CD8 T cells in people with metastatic non-small cell lung cancer NSCLC. This Phase 1 study aims to assess immune response after treatment with engineered tumor infiltrating lymphocyte TIL therapy by comparing imaging uptake before and after TIL infusion and ACZ redosing. Participants diagnosed with metastatic NSCLC will receive up to four infusions of zirconium Zr 89 crefmirlimab berdoxam, an investigational anti-CD8 minibody radiolabeled with Zirconium-89. Each infusion is followed by a PETCT scan about 24 hours later, with a timing window of plus or minus 3 hours. The study focuses on imaging changes from baseline to two weeks post-treatment. During the study, participants will undergo PETCT scans and infusions as scheduled. Researchers will measure differences in PET uptake to monitor CD8 T cell presence before and after treatment interventions. Safety and effectiveness of this imaging method will be tracked, with participation expected to last through the imaging and infusion period around the TIL therapy timeline.

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer